
The Medicare Cliff explained
In the United States, there are two government health insurance programs: Medicare and Medicaid. Usually, you become eligible for Medicare when you turn 65 years old. Medicaid eligibility, on the other hand, is determined by your income.
Older adults with limited incomes who are on Medicaid can also become eligible for Medicare based on Medicare's eligibility criteria. In some cases, however, you may lose your Medicaid benefits once you become eligible for Medicare. This is called the 'Medicare cliff.'
Read to learn about the Medicare cliff, its potential impact on your coverage and costs, and how you might manage its effect.
What is the Medicare CLIFF?
The Affordable Care Act (ACA) has generally expanded Medicaid coverage to people whose incomes are below 138% of the federal poverty level in most states.
Most U.S. states have implemented this expansion. In all U.S. states except Alaska and Hawaii, this is equivalent to an annual income of $21,597 for an individual, or higher, depending on family size.
But, the ACA's Medicaid expansion doesn't apply to people over 65, which means Medicaid eligibility criteria become more stringent once you turn 65. At this point, your income must be around 100% of the FPL, or $15,650 per individual, or even lower, depending on the state.
Although it is possible to be eligible for both Medicare and Medicaid, the 'Medicare cliff' happens when you lose eligibility for Medicaid coverage when you turn 65, forcing you to transition to Medicare coverage only.
Since Medicare's coverage structure and costs are different from those of Medicaid, transitioning from Medicaid to Medicare may lead to more out-of-pocket spending and sometimes less comprehensive coverage and benefits.
What is the impact of the Medicare CLIFF?
When you change from Medicaid to Medicare, you may face higher costs because Medicare has higher premiums, deductibles, copayments, and coinsurance than Medicaid.
Original Medicare (Part A and Part B) has particular costs that vary significantly from the costs of Medicaid. In 2025, if you pay for Medicare Part A, your premium is either $285 or $518, depending on your income, and your deductible is $1,676.
Once coverage begins, Part A covers full hospitalization for the first 60 days, after which additional daily costs apply. For Medicare Part B, the premium is $185 monthly, depending on income, with a $257 deductible, after which you cover 20% of the cost of your care.
On the other hand, Medicaid generally caps your out-of-pocket costs to no more than 5% of your family income. In many states, if your income is at or below 150% of the FPL (an income of $23,475 per individual), you also won't pay a premium. Also, if you fall into certain groups, you're entirely exempt from most out-of-pocket expenses, and some services, like emergency and preventive care, are entirely free.
In terms of coverage differences, Medicare doesn't cover long-term care expenses, whereas Medicaid does. Medicare also doesn't cover benefits like dental, vision, or hearing costs.
However, if you choose to enroll in Medicare Advantage (Part C) instead of Original Medicare, you may get these additional benefits, but you'll also have premiums, deductibles, and coinsurance. These will depend on your specific plan and may also be higher than your previous Medicaid costs. This is the same with Medicare Part D, which covers prescription drugs.
Who is impacted by the Medicare CLIFF?
Only about 1 in 10 people ages 65 and older, or 5.9 million people in the United States, have incomes below 100% of the FPL. Anyone whose income exceeds this threshold could lose their Medicaid coverage when they become eligible for Medicare.
That said, people who earn above 100% of the FPL don't necessarily earn a lot and don't necessarily find it easy to afford out-of-pocket medical expenses. In addition, the Medicare cliff disproportionally affects females assigned at birth (FAAB) and People of Color.
Broader impact of the Medicare cliff
Based on a 2025 data analysis of the Medical Expenditure Panel Survey and the National Health and Nutrition Examination Survey from 2007 to 2019, researchers found that the Medicare cliff can lead to as much as a 25% increase in out-of-pocket spending on healthcare. It also increases your likelihood of difficulty paying medical bills by as much as 44.4%.
In addition, a 2023 study also found that losing Medicaid as a result of the Medicare cliff significantly reduced enrollment and healthcare utilization for Black and Hispanic people, making it harder to access medical care due to higher costs, as compared to people who are white.
How do I avoid the Medicare CLIFF?
There isn't necessarily a way to avoid the Medicare cliff entirely, unless the ACA's Medicare expansion is expanded further to people over age 66. That said, under certain circumstances, you might be able to retain some Medicaid coverage or receive financial support for your higher Medicare costs. These include:
Medicare Savings Programs (MSPs): Qualifying for one of the four MSPs can help you cover your Medicare Part A and Part B premiums. Depending on the program, you might also retain some Medicaid benefits or have Medicaid cover part of your Medicare costs.
Medicaid for aged, blind, and disabled people (ABD Medicaid): If you qualify, you may be able to enroll in additional Medicaid programs, such as ABD Medicaid, for which you may still qualify once you turn 65.
Social Security Disability Insurance (SSDI): You can also qualify for Medicaid if you receive SSDI. Depending on your state, the FPL limit for qualifying based on disability could be different than the standard limit at age 65, allowing you to stay on Medicaid.
In addition, if you are losing your Medicaid and transitioning to Medicare, there are other things you can do to help you manage increased out-of-pocket costs. These include:
Extra Help: This program, also called the Part D Low-Income Subsidy, offers financial assistance for prescription medications based on your income. Under Medicare, you may qualify for Extra Help even if you no longer qualify for Medicaid.
State Pharmaceutical Assistance Program (SPAP): Some states may offe r SPAP, which is a program that can also help you pay for the cost of prescription drugs and Medicare Part D premiums.
Medigap: Medicare supplement plans, also called Medigap, can help you cover out-of-pocket costs remaining after your Original Medicare benefits kick in. These plans also come with a premium, but they can save you money on deductibles, copayments, and coinsurance. Whether Medigap is right for you depends on your budget and specific health needs.
Takeaway
Under the ACA, Medicaid expansion covers many adults until age 65. After this, stricter state-specific eligibility rules take effect, often leading to loss of coverage around the time you qualify for Medicare.
When you switch to Medicare from Medicaid, you can encounter higher costs and different benefits compared to Medicaid, which can pose both financial and health-based challenges.
This situation is referred to as the Medicare cliff, which tends to affect more FAABs and people living with at least two chronic conditions. It may also create more challenges for people from certain historically marginalized groups.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Tandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 8.5% year on year to $240.7 million. The company expects the full year's revenue to be around $1 billion, close to analysts' estimates. Its GAAP loss of $0.78 per share was significantly below analysts' consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q2 CY2025 Highlights: Revenue: $240.7 million vs analyst estimates of $237.1 million (8.5% year-on-year growth, 1.5% beat) EPS (GAAP): -$0.78 vs analyst estimates of -$0.39 (significant miss) Adjusted EBITDA: -$1.85 million vs analyst estimates of $2.34 million (-0.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $1 billion at the midpoint Operating Margin: -21.5%, down from -13.9% in the same quarter last year Sales Volumes rose 5% year on year, in line with the same quarter last year Market Capitalization: $1.01 billion Company Overview With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Tandem Diabetes grew its sales at an impressive 19.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Tandem Diabetes's annualized revenue growth of 12.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Tandem Diabetes also reports its number of pump shipments, which reached 21,000 in the latest quarter. Over the last two years, Tandem Diabetes's pump shipments averaged 2.9% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Tandem Diabetes reported year-on-year revenue growth of 8.5%, and its $240.7 million of revenue exceeded Wall Street's estimates by 1.5%. Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Adjusted Operating Margin Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits. Tandem Diabetes's high expenses have contributed to an average adjusted operating margin of negative 7.9% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, Tandem Diabetes's adjusted operating margin decreased by 15.6 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. Tandem Diabetes's adjusted operating margin was negative 13.2% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Tandem Diabetes's earnings losses deepened over the last five years as its EPS dropped 34.2% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Tandem Diabetes's low margin of safety could leave its stock price susceptible to large downswings. In Q2, Tandem Diabetes reported EPS at negative $0.78, down from negative $0.47 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Tandem Diabetes to improve its earnings losses. Analysts forecast its full-year EPS of negative $3.09 will advance to negative $1.00. Key Takeaways from Tandem Diabetes's Q2 Results It was encouraging to see Tandem Diabetes beat analysts' revenue expectations this quarter. On the other hand, its EPS missed and its sales volume fell short of Wall Street's estimates. Overall, this was a softer quarter. The stock traded down 17% to $12 immediately after reporting. Tandem Diabetes may have had a tough quarter, but does that actually create an opportunity to invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Inicia sesión para acceder a tu cartera de valores
Yahoo
2 hours ago
- Yahoo
Retiree health care costs are climbing: What advisors need to know
Health care costs for retirees just keep rising. A 65-year-old retiring in 2025 can expect to spend $172,500 on health care costs and medical expenses throughout retirement, according to a new survey from Fidelity. Financial advisors say ignoring that number can be a costly decision for retirees. Since Fidelity began tracking retiree health care costs in 2002 — when the estimated expense for a 65-year-old was just $80,000 — projected costs have steadily climbed, far outpacing inflation. In the past year alone, Fidelity reported a 4% increase in total expected health care spending for retirees. READ MORE: A health care planning checklist for financial advisorsLong-term care costs can derail retirement plans. Here's how to manage themWhy protecting wealth starts with planning for health careSocial Security is changing — here's how advisors are preparing The estimate includes out-of-pocket prescription drug costs, Medicare premiums and other medical expenses, such as co-payments and deductibles. Researchers did not include potential costs from other health care-related expenses, including over-the-counter medications, most dental services and long-term care. Many retirees have found themselves ill-equipped to handle those costs, according to Shams Talib, head of Fidelity Workplace Consulting. "Year after year, so many Americans underestimate how much they'll need to save to cover health care costs in retirement," Talib said. "We recognize the impact health care costs can have on retirement savings. With the right tools and guidance, pre-retirees and retirees alike can take greater control of their financial futures by beginning the planning process as soon as possible." Clearing up Medicare misconceptions Financial advisors say one of the biggest impediments to planning for health care costs in retirement is a misconception about the role of Medicare. Namely, that it will cover more medical expenses than it does. "When I have these conversations with clients, especially those who are unprepared, the first step is just helping them slow down," said Melissa Cox, owner of Future-Focused Wealth in Dallas, Texas. "There's often a mix of embarrassment and fear. Many say, 'I didn't know this was something I needed to think about.' We walk through Medicare together, clarify what's covered and what isn't, and start looking at how their current financial picture can support a more realistic health care forecast." That picture can start to look very different depending on how short they are of covering estimated medical expenses. "Sometimes we have to pivot, adjust spending, reframe goals or revisit timelines, but that's okay," Cox said. "What matters most is giving people a sense of control over something that felt out of reach." Encourage clients to plan early Preparing for health care costs in retirement can be a relatively straightforward process as long as clients start early, advisors say. Near-retirees have several cost-effective options to help cover expenses, including Medigap, long-term care insurance and life insurance with care-related riders. But for older retirees seeking coverage later, the process becomes more complex and often more expensive. According to Andrew Crowell, vice chairman of wealth management for D.A. Davidson in New York City, waiting too long to sign up for certain plans can make them difficult to obtain at all. "I've had some clients recently, in good health but in their 70s, who were looking for a little extra coverage. … Both of them [were] denied coverage because they couldn't pass a cognition test," Crowell said. "I have perfectly lucid conversations with them all the time, but the test that they were given was an individual over the phone reading a long list of words, and then they were asked to repeat back as many of the words they remembered hearing in the short space, and they froze up. They stammered through a few of them, and the insurance just denied them on that, and they have no aches, no pains, no typical aging stuff." If those same clients had tried to sign up for policies in their 50s or 60s, the situation would have looked very different, Crowell said. "If we had done that in their 60s or in their 50s — young, healthy — they would have qualified for a great preferred rate premium, and it wouldn't be an issue," he said. "Now they can try to reapply, but you know they're going to have the jitters from the minute they reapply, and they're probably going to freeze up again just because of that." Crowell, who has been working in the industry for over 30 years, said insurance companies are becoming more cautious when assessing people due to increasing longevity. When it's too late to start early Starting early is one of the most effective strategies in financial planning — and health care planning is no exception. But even for clients who come to an advisor later in life, there are still viable options to manage rising medical costs. "When I work with clients who are unprepared for these costs, the conversation often shifts to what they value most in their retirement plan," said Beau Kemp, a financial advisor at SwitchPoint Financial Planning in Lehi, Utah. "If the plan goes from looking good to looking constrained with the increased health care costs, we have to make some adjustments." Exactly what those adjustments look like depends on the client's lifestyle preferences, Kemp said. Clients set on maintaining their current lifestyle may need to delay retirement as they build up their savings. Others who are more concerned with retiring at a specific age may have to scale back their spending to make room for medical costs. "I rarely decrease the projected medical expenses in a plan because these costs are largely out of our control," Kemp said. "The focus needs to be on what we can control and if a client is comfortable with those adjustments. The goal is to create a plan that provides both financial security and peace of mind."
Yahoo
2 hours ago
- Yahoo
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif., August 06, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx," said John Hanna, CEO of CareDx. "His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase." In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. "On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO," said John Hanna. "Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best." About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts CareDx Media Contacts Natasha Moshirian Wagnernwagner@ Investor RelationsCaroline Cornerinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data